Navigation Links
Report Release: Trends in Treatment of America's Wounded Warriors
Date:11/8/2007

Psychological Traumas and Traumatic Brain Injuries: The Signature Wounds of Operation Iraqi Freedom and Operation Enduring Freedom

WASHINGTON, Nov. 8 /PRNewswire-USNewswire/ --- Veterans for America's "Trends in Treatment of America's Wounded Warriors" identifies a number of interrelated trends adversely affecting servicemembers and veterans suffering from the "signature wounds" of Iraq and Afghanistan - traumatic brain injury (TBI) and psychological traumas.

This report is the result of VFA's aggressive investigative program which identifies deficiencies in the treatment of service-connected neurological and/or mental health problems.

VFA investigators have visited every demobilization site in the United States and overseas, where they have monitored the quality of treatment, family support, rehabilitation, and other services that should enable a wounded servicemember to readjust to civilian life.

VFA has found that medical care for mental health and TBI is often inadequate or poorly delivered, and when a servicemember is discharged, decisions are often made by the military that negatively affect veterans for the rest of their lives.

VFA has also found that little consideration is given to TBI or PTSD in the military justice system despite the fact that these wounds are known to cause improper behavior.

Lack of capabilities to treat these injuries, inadequate adherence to the Congressional inquiry process, and the inability or unwillingness to treat PTSD and TBI as wounds of equal legitimacy as physical injuries are some problems that require improved military leadership.

This report incorporates VFA investigative findings with open-source DoD and other reports and articles to provide a comprehensive picture of the state of care for America's wounded warriors.

According to retired Brigadier General Dr. Stephen N. Xenakis, former Commanding General of the Southeast Regional Army Medical Command: "VFA's r
'/>"/>

SOURCE Veterans for America
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Virginia Tech Report Has National Importance
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
4. Haemacure Reports Third Quarter 2007 Results
5. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
6. Biotech Finishes on a High in August, Burrill Report Says
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. First New York/New Jersey Health Care Report Card Released
11. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... selected a Texas Wind Integration project team including Drummond Group ... smart grid demonstration project. Drummond Group,s role is overseeing the ... with strong support from the project stakeholders. , ... ... -- The Department of Energy has selected a ...
(Date:12/7/2009)... Content throughout the Clinical Workflow , ... ... Institutions currently using point-of-care resources from EBSCO Publishing ... benefit from a new agreement which gives healthcare providers ... retrieval of relevant and current information and improved quality ...
(Date:12/7/2009)... , ... Phoenix, AZ (PRWEB) December 7, 2009 -- ... spinal cord injury: The online retailer of medical supplies ... , ,Cure Medical is a forward-thinking manufacturer of catheters. In ... the company donates 10 percent of all of their pre-tax profits ...
(Date:12/7/2009)... agency A.R.M. Solutions was recognized as a leader in the ... award-winning recovery service outperforms traditional collection agencies in speed, cost, ... ... December 7, 2009 -- A.R.M. Solutions, a leading provider of ... Places to Work in Collections by insideARM.com. This is the ...
(Date:12/7/2009)... Cell Therapeutics, Inc. ("CTI") (Nasdaq and ... of St. George,s Hospital, University of London during ... Hematology ("ASH") Annual Meeting updated results from the ... of pixantrone (the "PIX 301 EXTEND trial") in ... patients who have failed 2 or more prior ...
Breaking Medicine News(10 mins):Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 2Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 3Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 4Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 2Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 3Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Collection Agency Named One of 2009 Best Places to Work 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5
... N.J., March 23 Siemens Financial Services, Inc. ... in tax-exempt financing to El Camino Hospital in ... used to acquire a variety of Siemens Medical ... new El Camino hospital under construction.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Krapf of Bear, DE, will travel to Washington, ... to meet with congressional leaders and gain their support ... a cure for epilepsy.Krapf, 13, is one of 37 ... Kids Speak Up! , a national program coordinated by ...
... COLUMBIA, S.C., March 23 /PRNewswire-USNewswire/ -- BlueCross ... state to participate in the third annual National Walk ... nationwide will encourage their employees to take part in ... workers to take time regularly during their lunch breaks ...
... Money and Improves Health With Advanced but Affordable ... money and save your health in these tough ... part medical detective as well as a skilled ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090323/NY86411-b ) , (Photo: ...
... that a disturbing number of children ,wag, breakfast claiming there ... ,can,t be bothered, having a meal before going to school. ... their children skip breakfast on three to five school days ... one or two school days. , The remaining 58% of ...
... of Liverpool have demonstrated how a single-celled organism, living ... Salmonella transmission to animals and humans. , ... contaminate almost any food type, causing diarrhoea, abdominal pain ... which can also cause typhoid fever has ...
Other Medicine News:Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Delaware Youth Shares Epilepsy Message on Capitol Hill 2Health News:S.C. BlueCross Issues National Walk at Lunch Day Challenge to Employers 2Health News:Saving Money While Protecting Your Health in Tough Economic Times 2Health News:Saving Money While Protecting Your Health in Tough Economic Times 3Health News:School kids 'wagging' breakfast are missing healthy brain fuel 2Health News:Study shows how Salmonella survives in environment 2
(Date:12/4/2009)... BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a ... today announced the initial development and successful testing of ... Axsun believes this proprietary optical engine design raises ... of laser-based designs for swept source OCT light sources. ...
(Date:12/4/2009)... Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an ... and Drug Administration seeking approval to market its 8mg ... owned by Takeda Pharmaceutical Company Limited. Watson,s 8mg ...
(Date:12/4/2009)... Neal Shore and E. David Crawford presented results for ... secondary end points of biochemical recurrence rate in a ... injection) or monthly leuprolide in prostate cancer patients during ... who received FIRMAGON 240/80 mg/month had a recurrence rate ...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 55116 1Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 55116 2Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 55116 3School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 1School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 2School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 3School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 4Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009 13658 1Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009 13658 2
... CR011-vcMMAE for ... melanoma -, - Preliminary Phase I/II results to be presented in June ... ... CRGN ), a clinical-stage biopharmaceutical company,focused on oncology, announced today that it has ...
... ORENCIA is a First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) ... (NYSE: BMY ) today announced that the U.S. Food ... symptoms in pediatric patients six years and older with moderately ...
Other Medicine Technology:CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10
... The Acuity LT Central Monitoring Station provides ... and ready to go right out of ... surveillance in specific care areas rather than ... ICU. As patient-to-caregiver ratios continue to climb ...
... oximetry without the weight or ... to full-featured capability, the 3775 ... that clinicians need, when they ... full-featured handheld oximeter is designed ...
... One of the smallest handheld oximeters available, ... solution for hospital, home care, transport, and ... features., ,PIr (relative perfusion index measurement) ... a dynamic numeric reflection of perfusion at ...
... and Researchers., ,S/5 Collect and S/5 Collect4 ... to collect data from Datex-Ohmeda monitors. Data can ... time intervals. With S/5 Collect you have ability ... an interface cable or connect directly from S/5 ...
Medicine Products: